Crossmark

Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound

Crossref DOI link: https://doi.org/10.1038/s41598-018-20362-9

Published Online: 2018-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Islam, Md. Koushikul

Strand, Mårten

Saleeb, Michael

Svensson, Richard

Baranczewski, Pawel

Artursson, Per https://orcid.org/0000-0002-3708-7395
Wadell, Göran

Ahlm, Clas

Elofsson, Mikael

Evander, Magnus
License Information

Text and Data Mining valid from 2018-01-31

Version of Record valid from 2018-01-31
More Information

Article History

Received: 3 July 2017

Accepted: 17 January 2018

First Online: 31 January 2018

Competing Interests

: Mikael Elofsson, Mårten Strand and Göran Wadell are shareholders in Eirium AB that holds the commercial rights to benzavir-2. For all other authors there are no conflicts of interest to declare. None of the authors have any financial or funding disclosures to present.

Document is current

Any future updates will be listed below